Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Persistent or worsening tingling, burning, or pins and needles sensations after starting Ozempic—especially if linked to low blood sugar episodes or local injection site reactions—can signal a red flag worthy of medical evaluation.
Several factors, including nutrient deficiencies, early neuropathy, or injection site infection, can influence symptom severity. See below for critical details to guide your next steps.
Starting a new medication can bring unexpected sensations. If you've recently begun taking Ozempic (semaglutide) and feel tingling, burning, or "pins and needles" in your skin or extremities, you're not alone. This guide explores "Ozempic dysaesthesia after starting," helps you understand when these sensations merit concern, and offers practical next steps.
Dysaesthesia is an abnormal, often uncomfortable feeling on or under the skin. It can include:
Common causes range from nerve irritation to medication side effects. While occasional mild tingling isn't usually serious, persistent or worsening symptoms should prompt further evaluation.
Ozempic is a GLP-1 receptor agonist used to manage type 2 diabetes and support weight loss. It:
Possible reasons dysaesthesia occurs after starting Ozempic:
Rapid blood sugar changes
Fast drops in glucose levels can trigger nerve irritation, leading to tingling or burning.
Fluid shifts and dehydration
Appetite changes or mild nausea may reduce fluid intake, concentrating electrolytes and affecting nerve function.
Nutrient absorption changes
Slower digestion may alter absorption of B vitamins or minerals like magnesium—key players in nerve health.
Injection-related irritation
Local skin reactions at the injection site can sometimes produce abnormal nerve sensations.
Use this checklist to track your symptoms. If you answer "yes" to several items, consider reaching out to a healthcare professional.
Onset & Timing
Location & Pattern
Intensity & Impact
Associated Signs
Blood Sugar Context
Duration & Progression
If you checked "yes" for multiple items—especially moderate to severe intensity or signs of low blood sugar—this warrants closer attention.
Dysaesthesia isn't automatically dangerous, but certain patterns raise concern:
These could indicate:
Most mild dysaesthesia improves with simple measures. Try the following:
Optimize Blood Sugar Control
Stay Hydrated & Balanced
Support Nerve Health
Rotate Injection Sites
Gentle Nerve Soothing
Regular Exercise & Stretching
If simple home strategies don't ease your discomfort within 1–2 weeks, or if you notice any of the following, please act promptly:
For a quick and confidential way to evaluate your symptoms and determine whether immediate medical attention is needed, try Ubie's free AI-powered Symptom Checker—a medically approved tool that helps you understand your health concerns and guides you toward the right level of care.
While dysaesthesia can be uncomfortable, most people on Ozempic don't experience serious nerve problems. By tracking your symptoms, optimizing hydration and nutrition, and maintaining good blood sugar control, you'll reduce the chance of persistent discomfort.
Stay informed but avoid undue worry. Small lifestyle tweaks often resolve mild nerve sensations. However, never hesitate to seek medical advice if you're concerned—early evaluation can prevent complications.
If you answered "yes" to any of the above, please speak to a healthcare professional. In urgent cases—severe hypoglycemia, spreading infection, or profound numbness—seek immediate medical attention or call emergency services.
Your health and comfort matter. If you're unsure what to do next, Ubie's Medically Approved Symptom Checker Chat Bot offers a free, AI-powered assessment that can help you decide whether to adjust your routine or connect with a doctor right away.
Above all, trust your instincts. Speak to a doctor about anything that could be life-threatening or serious. They will guide you on the safest path forward.
(References)
* Al-Sulaiti B, Al-Mohannadi D, El-Awaisi I, Murshed A, Aburub A, Al-Amer R, Salhi RA. Neurological adverse events in patients treated with glucagon-like peptide-1 receptor agonists: a disproportionality analysis from the WHO VigiBase database. Diabetes Res Clin Pract. 2023 Apr;202:110753. doi: 10.1016/j.diabres.2023.110753. Epub 2023 Feb 1. PMID: 36731505.
* Kim SJ, Kim KS, Jeong SJ, Park IH, Choe KH, Kim BJ. Peripheral Neuropathy Associated with Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Case Series. J Clin Neurol. 2022 Jan;18(1):108-112. doi: 10.3988/jcn.2022.18.1.108. Epub 2021 Dec 29. PMID: 34964177.
* Abdelhafez S, Shosha Y. Potential Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists on the Nervous System: A Systematic Review. Curr Neuropharmacol. 2024;22(2):373-381. doi: 10.2174/1570159X21666230303102324. PMID: 38515456; PMCID: PMC10960579.
* Mahato A, Dhungana S, Subedi P, Aryal MR, Pant S, Adhikari B, Dhakal P, Shrestha S. Neurological Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists: A Scoping Review. Cureus. 2023 Dec 15;15(12):e49410. doi: 10.7759/cureus.49410. PMID: 38222144; PMCID: PMC10790100.
* Wang M, Chen L, Huang S, Chen S, Zeng X, Liu Y. Central and peripheral nervous system effects of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Mar 15;14:1106886. doi: 10.3389/fendo.2023.1106886. PMID: 36998638; PMCID: PMC10059344.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.